Skip to main content

Candel Therapeutics, Inc.

CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001841387

In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding Candel Therapeutics, Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025All holders in Q3 2025

13F holders of CADL: Q3 2025 compared with Q4 2025
MeasureQ3 2025Q4 2025Change
Holders8184+3
Shares22.7M23.6M+965.6K (+4.3%)
Value$115.6M$133.5M+$17.9M (+15.5%)

New holders (13)

Institutions that held Candel Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to CADL in Q4 2025
InstitutionSharesValue% of portfolio
Colony Group, LLC81,816$462.3K0.00%
Torrey Growth & Income Advisors66,750$377.1K0.13%
Martingale Asset Management L P37,519$212.0K0.01%
Virtu Financial LLC26,832$152.0K0.01%
Krilogy Financial LLC24,000$144.2K0.00%
XTX Topco Ltd23,776$134.3K0.00%
Jane Street Group, LLC10,799$61.0K0.00%
ProShare Advisors LLC10,433$58.9K0.00%
China Universal Asset Management Co., Ltd.8,946$50.5K0.00%
Group One Trading, L.P.8,895$50.3K0.00%
Mirae Asset Global Investments Co., Ltd.2,668$15.1K0.00%
GF Fund Management Co. Ltd.1,078$6.09K0.00%
Caitong International Asset Management Co., Ltd1$60.00%

Sold out (10)

Institutions that held Candel Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of CADL in Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
Wellington Management Group LLP137,888$703.2K
Millennium Management LLC136,670$697.0K
Marshall Wace, LLP103,847$529.6K
Kovitz Investment Group Partners, LLC79,316$404.5K
Balyasny Asset Management LLC49,483$252.4K
EntryPoint Capital, LLC18,696$95.3K
Quadrature Capital Ltd13,831$70.5K
Quarry LP4,200$21.4K
EverSource Wealth Advisors, LLC86$439
SRS Capital Advisors, Inc.54$275